- Alpha Cognition Inc. (ACOG, Financial) will report first quarter 2025 financial results on May 15, 2025.
- The company is focused on developing treatments for neurodegenerative diseases, including Alzheimer's.
- A conference call is scheduled for May 15, 2025, at 4:30 PM ET to discuss the results.
Alpha Cognition Inc. (ACOG), a Vancouver-based biopharmaceutical company, is set to release its financial results for the first quarter of 2025 on May 15, after the close of markets. This announcement will provide insights into the company's financial health and operational updates for the quarter ending March 31, 2025.
Following the results release, Alpha Cognition will host a conference call to discuss the financial and operational performance. The call is scheduled for 4:30 PM ET on the same day. Investors and analysts can participate using the dial-in numbers: 1-877-407-9039 or 1-201-689-8470. Additionally, a live audio webcast will be available for those who prefer to listen online.
The company is known for its dedication to advancing treatments for neurodegenerative diseases, including Alzheimer's disease and mild Traumatic Brain Injury (mTBI). Its leading product, ZUNVEYL, is a novel acetylcholinesterase inhibitor, designed to have fewer gastrointestinal side effects, and positively impacts cognition by binding to neuronal nicotinic receptors.
Alpha Cognition is also developing ALPHA-1062 in combination with memantine for treating moderate to severe Alzheimer's dementia, reflecting its commitment to addressing unmet medical needs in this space.
